Neurogenic Bladder: Epidemiology, Diagnosis, and Management.
Panicker JN.
Semin Neurol. 2020 Oct;40(5):569-579. doi: 10.1055/s-0040-1713876. Epub 2020 Oct 16.
EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment.
Stein R, Bogaert G, Dogan HS, Hoen L, Kocvara R, Nijman RJM, Quadackers JSLT, Rawashdeh YF, Silay MS, Tekgul S, Radmayr C.
Neurourol Urodyn. 2020 Jan;39(1):45-57. doi: 10.1002/nau.24211. Epub 2019 Nov 13.
Automated closed-loop stimulation to inhibit neurogenic bladder overactivity.
Majerus S, Nguyen C, Brose S, Nemunaitis G, Damaser M, Bourbeau DJ.
Proc Inst Mech Eng H. 2024 Jun;238(6):619-627. doi: 10.1177/09544119231172272. Epub 2023 May 2.
Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin.
Ferreira A, Nascimento D, Cruz CD.
Int J Mol Sci. 2023 Feb 7;24(4):3273. doi: 10.3390/ijms24043273.
A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment.
Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, Amarenco G, Gamé X, Kirby R, Van Der Aa F, Cornu JN.
Eur Urol. 2019 Jun;75(6):988-1000. doi: 10.1016/j.eururo.2019.02.038. Epub 2019 Mar 26.
Adverse Effects of Intravesical OnabotulinumtoxinA Injection in Patients with Idiopathic Overactive Bladder or Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Studies.
Yu PH, Wang CC.
Toxins (Basel). 2024 Aug 5;16(8):343. doi: 10.3390/toxins16080343.
Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Cruz F, Nitti V.
Neurourol Urodyn. 2014 Jul;33 Suppl 3:S26-31. doi: 10.1002/nau.22630.
Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury.
Hamid R, Averbeck MA, Chiang H, Garcia A, Al Mousa RT, Oh SJ, Patel A, Plata M, Del Popolo G.
World J Urol. 2018 Oct;36(10):1517-1527. doi: 10.1007/s00345-018-2301-z. Epub 2018 May 11.
Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact.
Nitti V, Haag-Molkenteller C, Kennelly M, Chancellor M, Jenkins B, Schurch B.
Medicine (Baltimore). 2023 Jul 1;102(S1):e32377. doi: 10.1097/MD.0000000000032377.
Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.
Haab F.
Neurourol Urodyn. 2014 Jul;33 Suppl 3:S2-5. doi: 10.1002/nau.22636.
